Oura and Counsel Health Expand Partnership Through CMS ACCESS Model

The intersection of consumer wearable technology and formal clinical medicine achieved a significant milestone today as smart-ring manufacturer Oura announced an expanded partnership with Counsel, an artificial intelligence-native primary care provider. This collaboration is designed to leverage the Centers for Medicare & Medicaid Services Innovation Center’s Advancing Chronic Care with Effective Scalable Solutions Model, widely known as the ACCESS Model. By integrating continuous biometric monitoring with physician-led care on a national scale, the initiative aims to fundamentally reshape how chronic conditions are managed among aging populations in the United States.

Beginning in early 2027, Counsel will roll out specialized, AI-native chronic care programs targeting conditions such as hypertension, obesity, hyperlipidemia, and prediabetes. Crucially, these comprehensive clinical services will be provided at no out-of-pocket cost to eligible Medicare beneficiaries across nearly all U.S. states. The initiative represents a profound leap forward in preventative healthcare, shifting the paradigm from episodic, reactive treatment in traditional clinical settings to continuous, data-driven health management embedded directly into patients’ daily lives.

Background Context of the Collaboration

The partnership between Oura and Counsel is not entirely new; the two organizations initially joined forces in May of this year to bridge the persistent gap between personal health insights and clinical intervention. Historically, consumer health wearables have excelled at capturing continuous physiological data—such as heart rate variability, sleep stages, skin temperature, and daily activity metrics—but have often left users isolated when attempting to interpret what those trends mean for their long-term health.

By integrating Counsel’s medical AI infrastructure and network of board-certified physicians with the Oura App, the initial collaboration allowed members to seamlessly transition from passive data tracking to active clinician consultations. Users could share their trends during virtual visits, enabling doctors to make more informed diagnostic and therapeutic decisions. The success of this initial integration laid the groundwork for the current scaling effort under the CMS ACCESS Model, providing both companies with the regulatory framework, institutional backing, and patient population needed to evaluate the model’s efficacy on a macroeconomic scale.

Chronology and Implementation Timeline

The rollout of the expanded ACCESS-backed partnership is structured across a deliberate timeline leading up to full operational launch in early 2027.

Since the initial announcement and rollout of the Oura-Counsel integration in May, the primary focus has been on establishing foundational interoperability between consumer-facing biometric dashboards and clinical electronic health record systems. This phase allowed early adopters to test the waters of AI-assisted health interpretation, generating valuable user feedback and initial clinical metrics.

Throughout late 2024 and 2025, the focus shifts toward refining the AI-native diagnostic and triage protocols, ensuring that Counsel’s medical intelligence can effectively flag anomalies in elderly cohorts without overwhelming healthcare providers with false positives. Simultaneously, Oura has been optimizing its software ecosystem to handle the specific regulatory and consent requirements mandated by CMS programs.

As 2026 progresses, Oura plans to deploy targeted informational campaigns within its mobile application to identify and educate eligible members regarding the ACCESS program. Because Oura rings track continuous health metrics, the application can passively identify members who meet baseline clinical criteria for conditions like prediabetes or hypertension.

By early 2027, the formal clinical intake will commence. Counsel will independently verify clinical eligibility for Medicare beneficiaries who express interest, onboard them into the program, and initiate tailored care plans that utilize real-time Oura biometric data alongside on-demand physician access.

Supporting Data and Demographic Demographics

The decision to target Medicare beneficiaries through the ACCESS Model is underpinned by compelling demographic and behavioral data regarding Oura’s existing user base. Contrary to the common misconception that wearable technology is exclusively the domain of younger, tech-savvy demographics, individuals aged 65 and older represent one of Oura’s most engaged cohorts, characterized by exceptionally high daily application retention rates.

Furthermore, internal health metrics indicate a high prevalence of cardio-kidney-metabolic risk factors within this senior membership group. Notably, approximately 20% of Oura members aged 65 and older present with a body mass index of 30 or higher, placing them in the clinically obese category. This high concentration of risk factors underscores the acute relevance of the ACCESS program’s core focus areas: obesity, hypertension, hyperlipidemia, and prediabetes.

Early indicators of patient satisfaction from the initial May integration are robust. Oura members who utilized the Counsel integration and subsequently consulted with a physician rated their overall care experience an impressive 4.6 out of 5. This high rating highlights the perceived value of receiving immediate, context-aware medical advice rather than navigating the friction-heavy traditional healthcare referral system.

Official Statements and Industry Perspectives

Leadership from both organizations have emphasized the transformative potential of combining passive biometric tracking with active clinical oversight, particularly for vulnerable or chronically ill populations.

“Earlier in the year, we partnered with Counsel to help Oura Members move from health insights to clinical action,” said Dr. Ricky Bloomfield, Chief Medical Officer at Oura. “The ACCESS program gives us the opportunity to study that model at scale, and to better understand how continuous biometric data, combined with physician-led care, can support Medicare beneficiaries managing hypertension, obesity, and other early cardio-kidney-metabolic conditions.”

Dr. Bloomfield’s sentiments reflect a broader industry consensus that consumer wearables are transitioning from lifestyle accessories into legitimate medical-grade monitoring tools. By embedding these tools into a federally backed innovation model like ACCESS, Oura and Counsel are attempting to generate the rigorous empirical evidence required by regulatory bodies and health economists to prove that continuous monitoring reduces downstream acute care expenditures.

Broader Impact and Implications for the Healthcare Sector

The inclusion of Oura and Counsel in the CMS ACCESS Model signals a major policy and operational shift within the Centers for Medicare & Medicaid Services. Historically, federal healthcare programs have been slow to incorporate data originating from consumer-grade hardware due to concerns regarding data privacy, accuracy, interoperability, and equity in access.

By approving an initiative that explicitly relies on continuous biometric data captured via smart rings, CMS is acknowledging that modern health management requires real-world data generated outside the four walls of a traditional doctor’s office. Chronic conditions such as hypertension and prediabetes fluctuate daily, influenced by sleep quality, stress, physical activity, and dietary habits—variables that single-point office visits fail to capture adequately.

For Counsel, the partnership validates its AI-native primary care model. By utilizing artificial intelligence to triage patient data, synthesize continuous biometric streams, and flag high-risk anomalies for human physicians, Counsel can scale its operations far beyond the limitations of traditional brick-and-mortar primary care practices. This efficiency is critical for managing large populations of Medicare beneficiaries without sacrificing the quality or responsiveness of physician-led care.

For Oura, this partnership cements its transition into a serious player in digital therapeutics and preventative medicine. While the company built its reputation on sleep tracking and general wellness, alignment with federal healthcare initiatives opens entirely new distribution channels and validates the clinical utility of its hardware.

Enrollment and Next Steps

As the 2027 launch date approaches, Oura plans to release detailed, step-by-step guidance within the Oura App to help interested members navigate the eligibility and enrollment process. While Oura will serve as the informational bridge, notifying members about the availability of the program based on their app engagement and self-reported health profiles, Counsel will maintain complete autonomy over clinical screening. Counsel will independently verify medical eligibility in compliance with CMS guidelines, manage official program enrollment, and oversee all aspects of patient care delivery.

Ultimately, the collaboration between Oura and Counsel under the CMS ACCESS Model represents a pioneering blueprint for the future of geriatric medicine. By pairing the continuous, objective insight of consumer biometric hardware with the empathetic, intelligent oversight of modern AI-driven primary care, the initiative offers a scalable solution to some of the most persistent and costly chronic health challenges facing the American healthcare system today.